Navigation Links
Obstructive in Medical Technology

RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days

... rapid improvements of both irritative and obstructive urinary symptoms that were sustained for 12 ... (frequency, urgency, and nocturia), and obstructive (hesitancy, incomplete emptying, intermittency, ... sub-scores related to irritative symptoms and obstructive symptoms. Change in peak urinary flow rate (Qmax ...

Forest Laboratories, Inc. and Laboratorios Almirall, S.A. Provide an Update on the Aclidinium Bromide Clinical Development Program

... aclidinium bromide for the treatment of chronic obstructive pulmonary disease (COPD) will be conducted to ... related to the treatment of asthma, COPD (Chronic obstructive Pulmonary Disease), rheumatoid arthritis, ... (1) WHO fact sheet 315. May 2008. Chronic obstructive pulmonary Disease (COPD). ...

Pivotal Data Showed SYMBICORT(R) Improved Lung Function in Adults with COPD

... in Patients with Moderate to Very Severe Chronic obstructive Pulmonary Disease [poster]. CHEST, Oct. 25-30, ... in Patients with Moderate to Very Severe Chronic obstructive Pulmonary Disease [poster]. CHEST, Oct. 25-30, ... in Patients with Moderate to Very Severe Chronic obstructive Pulmonary Disease [poster]. CHEST, Oct. ...

Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD

... bromide, an investigational treatment for chronic obstructive pulmonary disease (COPD). Data from four ... mouth (2.8% of patients), exacerbation of chronic obstructive airways disease (1.7% of patients) and cough ... related to the treatment of COPD (Chronic obstructive Pulmonary Disease), asthma, psoriasis, rheumatoid ...

MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics

... for the potential treatment of asthma and chronic obstructive pulmonary disease (COPD). MAP0005 is ... treatment with combination therapy. Chronic obstructive pulmonary disease refers to several ... for the treatment of asthma and chronic obstructive pulmonary disease. Additional information about ...

Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs

... study for TPI 1020 in Chronic obstructive Pulmonary Disease (COPD), following promising ... study for TPI 1020 (formerly NCX 1020) in Chronic obstructive Pulmonary Disease (COPD). This study is expected ... hypertension, glaucoma and Chronic obstructive Pulmonary Disease (COPD). NicOx S.A. is ...

Mayo Clinic Physicians Report Findings from Research on Sleep Disorders

... with a variety of sleep disorders, including obstructive sleep apnea and sleep behavior disorders, at ... than 12 million people in the United States have obstructive sleep apnea, a potentially serious disorder in ... http://www.mayoclinic.org/sleep-disorders/ . obstructive Sleep Apnea Linked with Cardiovascular Problems ...

NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results

... a Phase 2 clinical trial of TPI 1020 in chronic obstructive pulmonary disease (COPD) in the second half of ... COPD trial later this year." About COPD Chronic obstructive pulmonary disease (COPD) is a disease ... drugs for respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. TOPIGEN ...

Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma

... are the largest segment of the worldwide market for asthma and chronic obstructive pulmonary disease (COPD) medications, in terms of dollar sales (1). The ... the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema. ...

Cordex Signs European Development Partnership for ATPotent(TM) Sperm Motility Drug

... target a recently discovered pathway in the pathophysiology of chronic obstructive pulmonary diseases. For further information regarding Cordex, please visit ... that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease may not be successful, the market may not be as ...

New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure

... AZOR, particularly in patients with severe aortic stenosis. Severe obstructive Coronary Artery Disease Patients, particularly those with severe obstructive coronary artery disease, may develop increased frequency, duration, or ...

Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures

... target a recently discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For further information regarding Cordex, please visit ... that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease may not be successful, the market may not be as ...

Duska Therapeutics Completes Corporate Name Change to Cordex Pharma

... target a recently discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For further information regarding Cordex, please visit ... that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease may not be successful, and that our technology may not ...

Duska Therapeutics Applies for Phase 3 Special Protocol Assessment

... target a recently discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. Forward-looking Statements This press ... to target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. The forward-looking statements are subject to risks and ...

Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI

... maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It ... to be presented at CHEST 2008. E. Rand Sutherland et. al. In Chronic obstructive Pulmonary Disease, Nebulized Formoterol Fumarate Provides Prolonged ...

Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)

... research resources are related to the treatment of asthma, COPD (Chronic obstructive Pulmonary Disease), rheumatoid arthritis, multiple sclerosis, psoriasis ... pending regulatory approval. (2) WHO fact sheet 315. May 2008. Chronic obstructive pulmonary disease (COPD). ...

Radius Selects First Preclinical Candidate From SARM Discovery Program for the Treatment of Muscle Loss and Other Musculoskeletal Conditions

... trauma, cancer, chronic kidney disease, end-stage renal disease, chronic obstructive pulmonary disease (COPD), and other diseases. About Sarcopenia About ... a significant impact on quality of life include cancer cachexia, chronic obstructive pulmonary disease (COPD), and chronic renal disease. ABOUT RADIUS ...

Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations

... AZOR, particularly in patients with severe aortic stenosis. Severe obstructive Coronary Artery Disease Patients, particularly those with severe obstructive coronary artery disease, may develop increased frequency, duration, or ...

AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication

... Diagnosis, Management, and Prevention. Global Initiative for Chronic obstructive Lung Disease. Retrieved on 1 Apr 2008. ... Strategy for the Diagnosis, Management, and Prevention of Chronic obstructive Pulmonary Disease, 2007. Retrieved on 21 Apr 2008. ...

NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020

... proof-of-concept of inhaled TPI 1020 in patients suffering from chronic obstructive pulmonary disease (COPD). TPI 1020 is a novel, anti-inflammatory ... new classes of inhaled drugs for respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. TOPIGEN is actively progressing two ...

Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress

... Congress, September 2007. Poster. 5. Global Initiative for Chronic obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; MCR Vision, Inc.; 2006 6. CDC, ...

Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder

... was launched in the United States in June 2009 and is indicated to improve wakefulness in patients with excessive sleepiness associated with treated obstructive sleep apnea (OSA), shift work sleep disorder, also known as shift work disorder (SWD), and narcolepsy. NUVIGIL is not currently indicated for the ...

Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237

... of a Phase III clinical study by Novartis, with NVA237, a once-daily, long-acting muscarinic antagonist (LAMA) for the treatment of chronic obstructive pulmonary disease (COPD). NVA237 is a dry powder formulation for oral inhalation of glycopyrronium bromide, a LAMA with a rapid onset of activity. ...

VivoMetrics(R) Introduces Next Generation LifeShirt Prototype, a Smart Garment That Delivers Real-time Vital Signs Remotely to Healthcare Providers

... research and academic institutions across a wide range of disease states, including sleep disordered breathing, congestive heart failure, chronic obstructive pulmonary disease and cystic fibrosis. For more information, visit www.lifeshirt.com . Forward-looking Statements This press release ...

New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease

... that increase the risk of infection) or have diabetes. Any type of cancer or a risk factor for developing cancer, for example, chronic obstructive pulmonary disease (COPD) or had phototherapy for psoriasis. Heart failure or any heart condition. Many people with heart failure should not ...

New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal

... debilitated patients, and patients with conditions accompanied by hypoxia, hypercapnia or decreased respiratory reserve such as: asthma, chronic obstructive pulmonary disease or cor pulmonale, severe obesity, sleep apnea syndrome, myxedema, kyphoscoliosis, CNS depression, or coma. In such patients, even ...

Ironwood Announces Linaclotide European Licensing Agreement with Almirall

... and wellbeing. The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD (chronic obstructive pulmonary disease), rheumatoid arthritis, multiple sclerosis, psoriasis, and dermatology. The company is also aiming to expand its development ...

Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial

... Its development pipeline of products includes Aridol for the diagnosis of asthma, Bronchitol for cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease (COPD), PXS25 for the treatment of lung fibrosis and PXS4159 for asthma. Founded in 1998, Pharmaxis is listed on the Australian ...

invivodata Certified to Deliver EXACT in COPD Trials

... The EXACT is a Patient-Reported Outcome (PRO) measure for evaluating the frequency, severity, and duration of acute exacerbations of chronic obstructive pulmonary disease (COPD) and chronic bronchitis (AECB) in international clinical trials. Developed by United BioSource Corporation's (UBC) Center ...

Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)

... with placebo, as measured by the International Prostate Symptom Score (IPSS). IPSS includes irritative (frequency, urgency, and nocturia), and obstructive (hesitancy, incomplete emptying, intermittency, and weak stream) symptoms. RAPAFLO also has been proven to significantly improve Qmax scores ...

Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203

... of MT203 for the treatment of rheumatoid arthritis and several other diseases, including multiple sclerosis, psoriasis, asthma and chronic obstructive pulmonary disease. "Since the start of our collaboration with Nycomed in 2007, we have made excellent progress on the preclinical development of ...

Mayo Clinic: Retired National Football League Linemen Have High Incidence of Sleep Apnea

... Living Heart Foundation, showed concerning health trends for retired NFL players: Retired NFL players are more prone to obesity and obstructive sleep apnea than the general population. Retired NFL players have an increased rate of metabolic syndrome, a condition increasingly linked ...

U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies' SUPERA Peripheral Stent

... objective of the trial is to demonstrate the safety and effectiveness of the SUPERA Interwoven Self-Expanding Nitinol Stent in treating subjects with obstructive SFA disease. SUPERA has demonstrated superior properties in engineering tests compared to nitinol laser cut slotted tube stents resulting in greater ...

Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression

... modafinil, in the third quarter of 2009. NUVIGIL is indicated to improve wakefulness in patients with excessive sleepiness associated with treated obstructive sleep apnea (OSA), shift work sleep disorder, also known as shift work disorder (SWD), and narcolepsy. NUVIGIL is not approved for the treatment of ...

Pharmaxis Announces New Drug Application Submission for Aridol(TM)

... Its development pipeline of products includes Aridol for the management of asthma, Bronchitol for cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease (COPD), PXS25 for the treatment of lung fibrosis and PXS4159 for asthma. Founded in 1998, Pharmaxis is listed on the ...

Implantable Defibrillators Lower Risk of Death in Older Heart Patients

... Previous studies of ICDs have been conducted in patients who are primarily younger than 75, and who have few complications such as diabetes, chronic obstructive lung disease or a history of stroke. This primary prevention study recruited 986 consecutive patients who had diminished left ventricular ...

NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis

... & Co., Inc., for the treatment of prevalent and underserved diseases, such as atherosclerosis, hypertension, widespread eye diseases and Chronic obstructive Pulmonary Disease (COPD). NicOx S.A. is headquartered in France and is listed on the NYSE Euronext Paris (Compartment B: Mid Caps). ...

Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results

... & Co., Inc., for the treatment of prevalent and underserved diseases, such as atherosclerosis, hypertension, widespread eye diseases and Chronic obstructive Pulmonary Disease (COPD). NicOx S.A. is headquartered in France and is listed on the NYSE Euronext Paris (Compartment B: Mid Caps). ...

FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain

... debilitated patients, and patients with conditions accompanied by hypoxia, hypercapnia or decreased respiratory reserve such as: asthma, chronic obstructive pulmonary disease or cor pulmonale, severe obesity, sleep apnea syndrome, myxedema, kyphoscoliosis, CNS depression, or coma. Patients receiving ...

Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated

... children 6 months-18 years of age; adults over 50 years of age; pregnant women; and anyone with chronic health conditions, such as asthma, chronic obstructive pulmonary disease (COPD), heart disease and diabetes. The CDC also recommends annual vaccination for caregivers and household contacts of high-risk ...
Other Contents
(Date:7/25/2014)... this false-color image from the Terra satellite show the different ... wildfires in Eastern Russia. The burn scars show up ... The wildfires have broken across the remote parts of Eastern ... image from the MODIS instrument, it is still possible ... Two recent image features noted below show the devastating number ...
(Date:7/25/2014)... and disrupted brain development is an essential part ... largely unknown. However, thanks to funding from the ... University (GW) researcher Anthony-Samuel LaMantia, Ph.D. may be ... to these key questions in the field of ... and physiology at the GW School of Medicine ...
(Date:7/25/2014)... 25 countries and 35 states will attend the ... Society of America (GSA) next week at the ... feature close to 500 presentations (including 70 talks) ... expression and regulation, functional genomics, chemical biology and ... variety of diseases. , Of special note ...
Breaking Biology News(10 mins):GW researcher receives grant to answer the how and why of autism during development 2Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2
(Date:7/28/2014)... brain was able to arouse animals receiving general anesthesia ... issue of Anesthesiology , investigators from Massachusetts General ... of either agent would move, raise their heads and ... to the ventral tegmental area (VTA). Stimulation of ... not induce the animals to wake up. , ...
(Date:7/28/2014)... The report, “Blowing Agents Market by Type, ... Forecasts to 2019” defines and segments the global ... the global consumption volume and value. , Browse ... figures spread through 226 Pages and in-depth TOC ... Blowing agents are highly utilized materials as a ...
(Date:7/28/2014)... test developed at University of Colorado Skaggs School of ... (July 28, 2014) An influential new test, discovered ... the CU School of Pharmacy, helps monitor the effectiveness ... of tenofovir/emtricitabine), which is taken once daily to prevent ... AIDS 2014 Conference and published in Lancet Infectious ...
(Date:7/28/2014)... Medicine (BUSM) report variants in a new gene, PLXNA4, ... (AD). The discovery of this novel genetic association may ... specifically. These findings appear in the Annals of ... dementia affecting 5.4 million Americans including 13 percent of ... percent of people age 85 and older. Genetic factors ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Recent research ... desk all day for years can lead to a ... cardiovascular disease. But using a standing desk, or an ... pain, often driving office workers back to a seated ... are designed to alleviate this leg pain and ...
Breaking Medicine News(10 mins):Health News:Stimulation of brain region restores consciousness to animals under general anesthesia 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 3Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 4Health News:HIV research findings made possible by a test developed at CU School of Pharmacy 2Health News:Researchers identify potential biomarker for AD 2Health News:New Standing Desk Anti-fatigue Mats from Martinson-Nicholls Reduce Leg Fatigue and Discomfort Working at Standing and Sit-to-Stand Desks 2
Other TagsOther Tags